title: Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites.
abstract: OBJECTIVE
  To explore efficacy and side effects of intrapleural or intraperitoneal lobaplatin for treating patients with malignant pleural or peritoneal effusions.
  
  
  METHODS
  Patients in Jiangsu Cancer Hospital and Research Institute with cytologically confirmed solid tumors complicated with malignant pleural effusion or ascites were enrolled into this study. Lobaplatin (20-30 mg/m2) was intrapleurally or intraperitoneally infused for patients with malignant pleural effusion or ascites.
  
  
  RESULTS
  From 2012 to 2013, intrapleural or intraperitonea lobaplatin was administered for patients with colorectal or uterus cancer who were previous treated for malignant pleural effusion or ascites. Partial response was achieved for them. Main side effects were nausea/vomiting, and bone marrow suppression. No treatment related deaths occurred.
  
  
  CONCLUSIONS
  Intrapleural or intraperitoneal infusion of lobaplatin is a safe treatment for patients with malignant pleural effusion or ascites, and the treatment efficacy is encouraging.
authors.affiliation: Department of Chemotherapy, JiangSu Cancer Hospital, Nanjing, Jiangsu, China. huangxinen06@ymail.com
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Guo-Li
authors.initials: GL
authors.lastname: Wei
authors.forename: Jie-Ge
authors.initials: JG
authors.lastname: Huo
authors.forename: Xiao-Ning
authors.initials: XN
authors.lastname: Wang
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Lu
authors.forename: Xue-Yan
authors.initials: XY
authors.lastname: Wu
authors.forename: Jin
authors.initials: J
authors.lastname: Liu
authors.forename: Jin
authors.initials: J
authors.lastname: Xiang
authors.forename: Ji-Feng
authors.initials: JF
authors.lastname: Feng
mesh_terms: D000230:Adenocarcinoma / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D001201:Ascites / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D003503:Cyclobutanes / Q000627:therapeutic use*; D004333:Drug Administration Routes; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008113:Liver Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D016066:Pleural Effusion, Malignant / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D003503:Cyclobutanes; D009944:Organoplatinum Compounds; C066228:lobaplatin